

P&CD copy

DOE/ER/60434--5

DE90 017335

**BORON IN NUCLEAR MEDICINE: NEW SYNTHETIC APPROACHES TO
PET, SPECT, AND BNCT AGENTS**

Progress Report

March 1, 1990 - February 28, 1991

George W. Kabalka

Department of Chemistry
University of Tennessee
Knoxville, Tennessee 37996-1600

OCTOBER 1990

PREPARED FOR THE U. S. DEPARTMENT OF ENERGY
UNDER GRANT NUMBER DE-FG05-86ER60434

DISCLAIMER

This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.

Approved by OCTI

SEP 18 1990
DISTRIBUTION OF THIS DOCUMENT IS UNLIMITED

MASTER

DISCLAIMER

This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.

DISCLAIMER

Portions of this document may be illegible in electronic image products. Images are produced from the best available original document.

TABLE OF CONTENTS

Section

I. Objective	3
II. Research Accomplishments	4
III. Bibliography of Publications Since Last Report	10
IV. Graduate and Postdoctorate Students	14
V. Budget	15

I. OBJECTIVE

The primary objective of the D.O.E. Nuclear Medicine Program at The University of Tennessee is the creation of new methods for introducing short-lived isotopes into agents for use in PET and SPECT. A small, but significant portion of our effort is directed toward the design of boron-containing neutron therapy agents. The uniqueness of the U.T. program is its focus on the design of new chemistry (molecular architecture) and technology as opposed to the application of known reactions to the synthesis of specific radiopharmaceuticals. The new technology is then utilized in nuclear medicine research at the U.T. Biomedical Imaging Center and in collaboration with colleagues at other D.O.E. facilities (Brookhaven National Laboratory, Oak Ridge National Laboratory, Los Alamos National Laboratory, and Oak Ridge Associated Universities).


An important goal of the D.O.E. Nuclear Medicine Program at U.T. is to provide training for students (predoctoral and postdoctoral) in the scientific aspects of nuclear medicine. The University of Tennessee is one of the very few institutions in the world where students have "hands-on" access to all modern nuclear medicine modalities: PET, SPECT and MRI. The academic nature of the program facilitates collaborative interactions with other D.O.E. nuclear medicine programs and helps to insure the continued availability of skilled scientists dedicated to the advancement of nuclear medicine.

II. RESEARCH ACCOMPLISHMENTS


I am pleased to report that this has been a productive year for the D.O.E. Program at Tennessee. Fifteen journal articles appeared in print since our last progress report. In addition, fourteen research abstracts of oral presentations have been published.

A. New Isotope Incorporation Reactions


1. Iodination: We have continued to develop new routes for radioiodinating physiologically active agents. The most versatile route involves the direct reaction of no-carrier-added sodium [¹²³I]-iodide with organoboranes. Utilizing this new methodology, we have synthesized a variety of radioiodinated agents for use in nuclear medicine. Since our last progress report, we have reported the syntheses of



a new series of radioiodinated α -iodovinylestradiols (I) an improved preparation of 3-QNB (II), and a new allose derivative (II).




I



II

We also reported the use of polymeric reagents for the synthesis of nitrogen-13 labeled amines. The procedure has the advantage that no soluble byproducts contaminate the desired product.



Microprocessor controlled units are currently under development.


[Section IIIa, articles 7, 9, and 11; Section IIIb, abstracts 5 and 7.]

4. Carbon-11: We continue to investigate the potential use of carbon-11 in the synthesis of labeled steroids and amino acids for possible use in clinical PET.

[Section IIIb, abstracts 1 and 11.]

B. Technetium-Boron Complexes


Boronic acid derivatives of technetium-dioxime complexes, such as IV, have great potential as a single photon agents (SPECT) in nuclear medicine:




TcBr(cyclotriphosphorotriamine)₂

IV

The preparation of functionally substituted boronic acids, $\text{RB}(\text{OH})_2$, could result in organ specific technetium-labeled agents which parallel successful PET agents. Our group is experienced in boronic acid technology and we are currently attempting to synthesize a variety of functionally substituted boronic acids for use in complexes such as IV. We are also in the process of developing boronic acid analogs of estradiol (V) and QNB (VI).



V




VI

[Section IIIa, article 1; Section IIIb, abstracts 3 and 6.]

C. Boron-Neutron-Capture


We have collaborated with the Brookhaven National Laboratory Group (Dr. Dan Slatkin) for nearly seven years in the area of

BNCT. To date, the interaction has been focused on designing new BCNT agents. Agents of current interest involve ortho-carboranes which are rich in boron but behave like phenyl groups in organic




[where: ○ = BH and ● = CH]

synthesis. Our group is currently investigating the syntheses of reagents such as VII and VIII which could be used to label monoclonal antibodies by attachment to terminal amino or thio functional groups.



VII



VIII

[Section IIIb, abstract 4.]

III. BIBLIOGRAPHY OF PUBLICATIONS SINCE PREVIOUS REPORT

A. Journal Articles

1. "Synthesis of 3-Quinuclidinyl Benzilate Derivatives", G. W. Kabalka, S. B. Mathur, and Y-Z Gai, Org. Prep. Proc. Int., **22**, 87(1990).
2. "Oxidation of Organoboranes with Sodium Percarbonate," B. W. Kabalka, P. P. Wadgaonkar, and T. M. Shoup, Organometallics, **9**, 1316 (1990).
3. "Synthesis and Biological Evaluation of 3-C((E)-2-[1-125]Iodoethenyl)-D-allose: A New Strategy for the Preparation of In Vivo Stable Radioiodinated Carbohydrates", M. Goodman, G. W. Kabalka, F. F. Knapp, Nuc. Compac., **22**, 62 (1990).
4. "Rat Monoclonal Antibody Distribution in Mice: An Epitope Inside the Lung Vascular Space Mediates Very Efficient Localization", S. J. Kennel, S. Bultman, R. Lee, and G. W. Kabalka, Nucl. Med. Biol. **17**, 193 (1990).
5. "Highly Efficient Immunoliposomes Prepared with a Method Which is Compatible with Various Lipid Compositions," E. Holmberg, K. Maruyama, D. C. Litzinger, S. Wright, M. Davis, G. W. Kabalka, S. J. Kennel, and L. Huang, BBRC, **165**, 1272 (1989).
6. "The Reduction of Azides With Borohydride Supported on an Ion Exchange Resin", G. W. Kabalka, P. P. Wadgaonkar, and N., Chatla, Synth Commun., **20**, 293, (1990).
7. "Preparation of Isomerically Pure Dialkylamines Via the Reaction of Dimethylalkylboranes with Chloralkylamine", G. W. Kabalka and Z. Wang, Synth. Commun., **20**, 231, (1990).
8. "Sodium Perborate: A Mild and Convenient Reagent for Efficiently Oxidizing Organoboranes", G. W. Kabalka, T. M. Shoup, N. M. Goudgaon, J. Org. Chem., **54**, 5930 (1989).
9. "The Synthesis of Nitrogen-13 Labeled Butylamine Using Organoborane Polymers," J. Labeled Compd. Radiopharm., **24**, 90 (1989).

10. "The Synthesis of a Polymeric Organoborane for the Preparation of [¹⁵O]-butanol," G. W. Kabalka, J. F. Green, and G. McCollum, J. Labelled Compd. Radiopharm., **24**, 76 (1989).
11. "The Synthesis of Radiolabeled Compounds Via Organometallic Intermediates," G. W. Kabalka and R. S. Varma, Tetrahedron, **45**, 6601 (1989).
12. "Preparation of Isomerically Pure Alkylamines Via the Reaction of Dimethylalkylboranes with Chloramine," G. W. Kabalka, Z. Wang, and N. M. Goudgaon, Synth. Commun., **19**, 2409 (1989).
13. "Sodium Percarbonate: A Convenient Reagent for Efficiently Oxidizing Organoboranes," G. W. Kabalka, P. P. Wadgaonkar, and T. M. Shoup, Tetrahedron Lett., **38** 5103 (1989).
14. "Trimethylsilyl Esters: Temporary Protection of Carboxylic Acids During Hydroboration Reactions," G. W. Kabalka and D. E. Bierer, Synth. Commun., **19**, 2783 (1989).
15. "The Reduction of α,β -Unsaturated Nitroalkenes to Nitroalkanes with Borohydride Supported on an Anion Exchange Resin," N. M. Goudgaon, P. P. Wadgaonkar and G. W. Kabalka, Synth. Commun. **19**, 805 (1989).

B. Research Presentations

1. "Synthesis of Radiopharmaceuticals Via Organoboranes", G. W. Kabalka, American Chemical Society Meeting, Washington, D.C. (August, 1990).
2. "The Novel Asymmetric Allyl- and Crotylboration of α -Hydroxyketones", Z. Wang, X Meng, and G. W. Kabalka, American Chemical Society Meeting, Washington, DJ.C. (August, 1990).
3. "Synthesis of a New Series of 17- α -Iodovinyl-estradiols". G. W. Kabalka, T. M. Shoup, Boron USA II Workshop, Raleigh, NC (June, 1990).
4. "Use of Organoboranes in Modern Medical Imaging", G. W. Kabalka, Boron USA II Workshop, Raleigh, NC (June, 1990).

5. "Preparation of Isomerically Pure Diamines and Amino Acid Via Hydroboration-Amination Reactions", G. W. Kabalka and Z. Wang, Boron USA II Workshop, Raleigh, NC (June, 1990).
6. "Synthesis of a New Series of 17 α -Iodovinylestradiols Via Boranes", G. W. Kabalka, T. M. Shoup, and M. M. Goodman, International Symposium on Radiopharmaceutical Chemistry, L-05, Princeton, NJ (June, 1990).
7. "Synthesis of Organoborane Polymers for Use in the Preparation of Nitrogen-13 Labeled Amines", G. W. Kabalka, J. F. Green, M. M. Goodman, Z. Wang, and P. P. Wadgaonkar, International Symposium on Radiopharmaceutical Chemistry, K-12, Princeton, NJ (June,, 1990).
8. "Synthesis and Evaluation of Flourine-18-Labeled 4-0-3-Fluoropropyl-D-glucose and 4-0-3-Fluoro-propyl-2-deoxyglucose: Potential Agents for the Assessment of Local Glucose Transport and Perfusion in the Brain and Heart", M. M. Goodman, G. W. Kabalka, X. Meng, G. B. Daniel, C. P. D. Longford, G. T. Smith, and M. K. Hunter, International Symposium on Radiopharmaceutical Chemistry, H-15, Princeton, NJ (June, 1990).
9. "Synthesis of Iodine-123 Labeled 4-0-(E)-3-Iodopropen-2-yl-2-deoxy-D-glucose and 4-0-(E)-Iodopropen-2-yl-glucose as Potential Brain and Heart Imaging Agents", M. M. Goodman, G. W. Kabalka, X. Meng, G. B. Daniel, and C.P.D. Longford, International Symposium on Radiopharmaceutical Chemistry, Princeton, NJ (June, 1990).
10. "Synthesis of Iodine-123 Labeled 3-0-(E)-3-Iodopropenyl-D-glucose: A Potential New Agent for the Assessment of Glucose Transport Into the Brain and Heart Using Spect", M. M. Goodman, G. W. Kabalka, R. N. Waterhouse, and G. B. Daniel, International Symposium on Radiopharmaceutical Chemistry, Princeton, NJ (June, 1990).
11. "A Microprocessor-Controlled Radiochemistry System for the Automated Preparation of Carbon-11 Amino Acids", M. M. Goodman, J. L. DeVinney, C.P.D. Longford, M. Ladetsky, G. W. Kabalka, J. Larsen, K. F. Hubner, E. Buonocore, International Symposium on Radiopharmaceutical Chemistry, E-14, Princeton, NJ (June, 1990).

12. "Computer Controlled Synthesis of Oxygen-15 Butanol and Water. Automated Production and Dispensing Systems", M. M. Goodman, J. L. DeVinney, G. W. Kabalka, C.P.D. Longford, M. Ladetsky, and J. F. Green, International Symposium on Radiopharmaceutical Chemistry, E-05, Princeton, NJ (June, 1990).
13. "Synthesis and Evaluation of Radioiodinated 4-O-(E)-3-Iodopropen-2-yl-D-glucose and Derivatives as Potential Heart Imaging Agents", M. M. Goodman, G. W. Kabalka, X. Meng, G. B. Daniel and C.P.D. Longford, Society of Nuclear Medicine Meeting, Washington, D.C. (June, 1990).
14. "The Diels-Alder Reaction of Methyl Acrylate and Cyclopentadione on γ -Alumina", G. Hondrogiannis, R. M. Pagni, G. W. Kabalka, P. Anosike, and R. Kurt, American Chemical Society Meeting, ORGN 329, Boston, MA (April, 1990).

IV. GRADUATE AND POSTDOCTORAL STUDENTS

Four postdoctoral students and three graduate students were supported during this period by the Department of Energy Nuclear Medicine Program.

a. Postdoctoral Students

Dr. Timothy Shoup

Dr. Laila H. M. Guindi

Dr. Chatla Narayana

b. Graduate Students

Mark A. Davis (Ph.D. candidate - Ph.D. 1990)

R. David Pace (Ph.D. candidate)

Stephen J. Lambert (Ph.D. candidate)

Elizabeth Zippi (Ph.D. candidate)